In short
Clinical trials are studying GXV813 in hospitalized adults with schizophrenia. These studies aim to assess safety, tolerability, and treatment response, especially in people with an acute episode. The current trial is in Phase 2 and compares GXV813 with placebo.
Key points
- Current clinical trial data show GXV813 being studied in hospitalized adults with schizophrenia who are having an acute episode. The trial is a Phase 2 interventional study with 142 participants. Researchers are comparing GXV813 with placebo. The main measure is the change in PANSS total score after 6 weeks. The study also focuses on safety, tolerability, and treatment response.
Trial overview
The available clinical trial for GXV813 is a Phase 2 interventional study called STAR-1. It is authorised and includes 142 participants.
The study is designed to assess the safety, tolerability, and treatment response of GXV813 in people with schizophrenia. The trial compares GXV813 with placebo to see whether the study drug improves symptoms.
Who is being studied
This study focuses on hospitalized adults with schizophrenia who are having an acute episode. The trial summary says the participants are adult inpatients diagnosed according to DSM-5 criteria.
In simple terms, this means the study is looking at people who are currently in the hospital and whose symptoms are active enough to need close care.
What is being measured
The main endpoint is the change from baseline in PANSS total score at 6 weeks. Baseline means the starting point before treatment begins.
PANSS stands for Positive and Negative Symptom Scale, which is a rating tool used to measure schizophrenia symptoms. A change in this score helps researchers see whether symptoms improve, worsen, or stay the same over time.
Trial design and treatment groups
The study is interventional, which means researchers assign the treatment rather than just observing what happens. The interventions listed are GXV813 given orally and placebo in hard gelatin capsule form.
Placebo is a comparison treatment that does not contain the active study drug. Using placebo helps researchers judge whether any symptom change is due to GXV813 rather than chance or other factors.
Why this study matters
Schizophrenia can affect both positive symptoms, such as hallucinations or delusions, and negative symptoms, such as low motivation or reduced speech. This trial is important because it focuses on both types of symptoms in a hospital setting where people may need close monitoring.
Because the study is in Phase 2, it is part of the process of learning whether GXV813 may help people with schizophrenia and how it performs in a larger patient group.